Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: A comparison with MDMA

Pharmacology Biochemistry and Behavior

Volumn 65, Issue 2, 2000, Pages 233-240

  Barrionuevo, Meritxell ^a   Aguirre, Norberto ^a   Del Río, Joaquín ^a   Lasheras, Berta ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

3,4 Methylenedioxyethamphetamine (MDEA); 5 HT transporter; 5 HT(1A) receptor; 5 Hydroxytryptamine (serotonin, 5 HT); Corticosterone; Learning; Memory; Neurotoxicity

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CORTICOSTERONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; HYPERTHERMIA; LEARNING DISORDER; LONG TERM MEMORY; MALE; NEUROTOXICITY; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM; TASK PERFORMANCE;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; AVOIDANCE LEARNING; CARRIER PROTEINS; DESIGNER DRUGS; FRONTAL LOBE; HIPPOCAMPUS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; PAROXETINE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 0033966572     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00170-7     Document Type: Article

References (40)

1. 1A receptor density and 8-OH-DPAT-induced hypothermia. Blockade by drugs preventing 5-hydroxytryptamine depletion Eur. J. Pharmcol. 346:1998;181-188.
2. Aguirre N., Barrionuevo M., Lasheras B., Del Río J. The role of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rats. J. Pharmacol. Exp. Ther. 286:1998;1159-1165.
3. 1A receptor density and mRNA expression in rat hippocampus, frontal cortex, and brainstem. The role of corticosteroids J. Neurochem. 68:1997;1099-1105.
4. 3 receptor antagonist with anxiolytic-like properties in animal models Psychopharmacology (Berlin). 117:1995;137-148.
5. Berger U.V., Gu X.F., Azmitia E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmaol. 215:1992;153-160.
6. Boja J.W., Schechter M.D. Possible serotonergic and dopamineric mediation of the N-ethyl-3,4-methylenedioxyamphetamine discriminative stimulus. Eur. J. Pharamcol. 202:1991;347-353.
7. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 51:1998;1532-1537.
8. Buhot M.C. Serotonin receptors in cognitive behaviors. Curr. Opin. Neurobiol. 7:1997;243-254.
9. 1A receptor agonist, impairs performance in a passive avoidance task. Eur. J. Pharmacol. 211:1992;227-234.
10. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res. Rev. 18:1993;1-32.
11. Colado M.I., Green A.R. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents "ecstasy"-induced neurodegeneration of 5-hydroxytrptamine neurones. Eur. J. Pharmacol. 280:1995;343-346.
12. 3H-PAT Nature. 305:1983;140-142.
13. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berlin). 119:1995;247-260.
14. Hegadoen K.M., Baker G.B., Coutts R.T. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain. J. Pharmacol. Toxicol. Methods. 34:1995;117-123.
15. Henry J.A., Jefferys K.T., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet. 340:1992;384-387.
16. Hiramatsu M., Kumagai Y., Unger S.E., Cho A.K. Metabolism of methylenedioxymethamphetamine. Formation of dihydroxymethamphetamine and quinone identified as its glutathione adduct J. Pharmacol. Exp. Ther. 254:1990;521-528.
17. Huether G., Zhou D., Rüther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its cogeners. J. Neural. Transm. 104:1997;771-794.
18. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 18:1998;5086-5094.
19. 3H]-paroxetine binding in rat brain. J. Neurochem. 50:1988;1783-1790.
20. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
21. Milroy C.M., Clarck J.C., Forrest A.R. Pathology of deaths associated with "ecstasy" and "eve" misuse. J. Clin. Pathol. 49:1996;149-153.
22. 1A receptor involvement in passive avoidance in the rat. Br. J. Pharmacol. 125:1998;499-509.
23. Morgan M.J. Memory deficits associated with recreational use of "ecstasy." Psychopharmacology (Berlin). 141:1999;30-36.
24. Nash J.F., Meltzer H.Y., Gudelsky G.A. Elevation of serum prolactine and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 245:1988;873-879.
25. Nash J.F., Nichols D.E. Microdialysis studies on 3,4-methylenedioxymethamphetamine and structurally related analogues. Eur. J. Pharmacol. 200:1991;53-58.
26. O'Shea E., Granados R., Esteban B., Colado M.I., Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ("ecstasy"). Neuropharmacology. 37:1998;919-926.
27. Parrott A.C., Lees A., Garnham N.J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA or "ecstasy" Evidence for memory deficits J. Psychopharmacol. 12:1998;79-83.
28. Pérez-Otaño I., Herrero M.T. Oñset, C.; De Ceballos, M. L.; Luquin, M. R.; Obeso, J. A.; Del Rió, J. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset Brain Res. 567:1991;127-132.
29. Ricaurte G.A., Finnegan K.F., Nichols D.E., DeLanney L.E., Irwin I., Langston J.W. 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur. J. Pharmacol. 137:1987;265-268.
30. Ricaurte G.A., Markowska A.L., Wenk G.L., Hatzidimitriou G., Wlos J., Olton D.S. 3,4-Methylenedioxymethamphetamine, serotonin and memory. J. Pharmacol. Exp. Ther. 266:1993;1097-1105.
31. Santucci A.C., Knott P.J., Haroutunian V. Excessive serotonin release, not depletion, leads to memory impairments in rats. Eur. J. Pharmacol. 295:1996;7-17.
32. 1B receptor. Psychopharmacology (Berlin). 141:1999;154-162.
33. Schmidt C.J. Acute administration of methylenedioxymethamphetamine. comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs Eur. J. Pharamcol. 136:1987;81-88.
34. 2 receptors. Brain. Res. 529:1990;85-90.
35. Series H.G., Molliver M.E. Immunocytochemical evidence for serotonergic neurotoxicity of N-ethyl-methylenedioxyamphetamine (MDE). Exp. Neurol. 128:1994;50-58.
36. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 19:1998;427-442.
37. Stone D.M., Johnson M., Hanson G.R., Gibb J.W. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol. 134:1987;245-248.
38. Tehan B., Hardern R., Bodenham S. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ("Eve"). Anaesthesia. 48:1993;507-510.
39. 1A receptor agonist 8-OH-DPAT on spatial short-term working memory in rats. Behav. Brain Res. 84:1997;247-258.
40. Wolff K., Hay A.W., Sherlock K., Conner M. Contents of "ecstasy." Lancet. 346:1995;1100-1101.